Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals Incorporated    VRTX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Vertex Pharmaceuticals Incorporated : Stock Price of Vertex Pharmaceuticals Incorporated Decreases -0.73%

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/07/2017 | 09:16am CET

Stock price performance of Vertex Pharmaceuticals Incorporated is analyzed for various periods using several stock trading signals. The stock price have dropped -5.73% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -11.51% . Looking at the past 52 week period, the stock price is up at 0.14% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Vertex Pharmaceuticals Incorporated has a negative value of -7.32 compared to overall market performance. For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a 20-day Moving Average of 8.74% and the 50-Day Moving Average is 8.19%.The 200 Day SMA reached 0.36%

Vertex Pharmaceuticals Incorporated is having a Relative Strength Index of 65.05 which indicates the stock is not yet over sold or over bought based on the technical indicators. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has tumbled 0.73% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 9.25% in the last four weeks. The stocks have underperformed the S&P 500 by 0.85% during the past week but Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) it has outperformed the index in 4 weeks by 8.27%.

Company has reported several Insider transactions to the SEC, on Feb 3, 2017, Michael Parini (EVP, CLO & CAO) sold 3,450 shares at 85.98 per share price.On Feb 3, 2017, Jeffrey Chodakewitz (EVP GMDA, CMO) sold 1,900 shares at 85.50 per share price.On Jan 13, 2017, Joshua S Boger (director) sold 8,000 shares at 83.15 per share price.

Vertex Pharmaceuticals Incorporated Last issued its quarterly earnings results on Jan 25, 2017. The company reported $0.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.06. Analyst had a consensus of $0.29.Analysts expectations of $ 452.50.During the same quarter in the previous year, the company posted $0.17 EPS.

Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Vertex Pharmaceuticals Incorporated was Reiterated by Stifel on Jan 26, 2017 to Buy, Lowers Price Target to $ 100 from a previous price target of $108 .Vertex Pharmaceuticals Incorporated was Initiated by Oppenheimer to Perform on Dec 15, 2016.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) : On Friday heightened volatility was witnessed in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) which led to swings in the share price. The stock opened for trading at $87.1 and hit $87.27 on the upside , eventually ending the session at $86.73, with a gain of 0.01% or 0.01 points. The heightened volatility saw the trading volume jump to 1,227,304 shares. The 52-week high of the share price is $103.73 and the company has a market cap of $21,512 million. The 52-week low of the share price is at $71.46 .

Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery.

(c) 2017 2016 Daily News Egypt. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERTEX PHARMACEUTICALS INC
02/07 VERTEX PHARMACEUTICALS INCORPORATED : Stock Price of Vertex Pharmaceuticals Inco..
01/28 VERTEX PHARMACEUTICALS INCORPORATED : U.S. Patents Awarded to Inventors in Calif..
01/28 INGERSOLL RAND : U.S. Patents Awarded to Inventors in New Jersey (Jan. 28)
01/25 VERTEX PHARMACEUTICALS INC / MA : Results of Operations and Financial Condition,..
01/25 VERTEX PHARMACEUTICALS INCORPORATED : tops Street 4Q forecasts
01/25 VERTEX PHARMACEUTICALS INCORPORATED : Reports Full-Year and Fourth-Quarter 2016 ..
01/19 MERCK KGAA : Darmstadt, Germany, Licenses Four Oncology Research and Development..
01/19 MERCK KGAA : Darmstadt, Germany Licenses Four Oncology Research and Development ..
01/14 VERTEX PHARMACEUTICALS INCORPORATED : Merck expands oncology portfolio with four..
01/12 VERTEX PHARMACEUTICALS INCORPORATED : Announces Upcoming Presentation at the J.P..
More news
Sector news : Bio Therapeutic Drugs
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
02/13 TEVA PHARMACEUTICAL INDUSTRIES : seeks CEO with pharma background to lead recove..
02/09DJAppeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol Drug
02/08 Weak pound buoys GSK but drugmaker warns on 2017 generic threat
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
02/09 Buying Growth Is A Tricky Choice For Gilead
02/09 Darzalex And Keytruda Win 2016's Sell-Side Popularity Contest
02/02 Dosing underway in Galapagos' mid-study study of CF candidate GLPG2222
02/01 Will FDA And Tax Reform Occur And Help Biotech Stocks?
01/26 Concert Pharmaceuticals Set For A Transformational 2017
Advertisement
Financials ($)
Sales 2017 2 037 M
EBIT 2017 419 M
Net income 2017 148 M
Finance 2017 876 M
Yield 2017 -
P/E ratio 2017 118,15
P/E ratio 2018 44,53
EV / Sales 2017 10,3x
EV / Sales 2018 7,93x
Capitalization 21 909 M
More Financials
Chart VERTEX PHARMACEUTICALS INC
Duration : Period :
Vertex Pharmaceuticals Inc Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Full-screen chart
Technical analysis trends VERTEX PHARMACEUT...
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 99,0 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith EVP, Chief Operating & Financial Officer
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Joshua S. Boger Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS..19.90%21 909
AMGEN, INC.18.52%127 620
CELGENE CORPORATION4.67%94 258
GILEAD SCIENCES, INC.-2.46%92 024
REGENERON PHARMACEUTIC..1.11%39 375
ACTELION LTD21.09%28 677
More Results